Skip to main content

Table 1 Ten-years disease/mortality, children ≤59 months, multiple PCV13 catch-up scenarios, assuming 6 years to indirect effects

From: Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

 

PCV7

PCV13 with no catch-up

Catch-up 39%

Catch-up 87%

Cases prevented due to catch-up (39%)

Additional cases potentially prevented with increased catch-upa

IPD

50,762

22,261

20,148

18,822

2,113

1,327

Hospitalized Pneumonia

1,203,733

940,580

916,018

900,426

24,562

15,592

Non-hospitalized Pneumonia

14,828,732

14,037,214

13,958,633

13,905,915

78,581

52,718

AOM

161,033,859

144,731,659

143,125,025

142,466,963

1,606,634

658,062

Deaths

4,389

3,141

3,051

3,020

90

31

  1. AOM: acute otitis media; IPD: invasive pneumococcal disease; PCV7: 7-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.
  2. aFrom 39% to 87%.